Edgewise Therapeutics, Inc. EWTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $157.28M+15.6% | $151.39M+19.2% | $144.17M+21.9% | $138.91M+26.5% | $136.03M+37.8% | ||
| $42.28M+24.3% | $40.02M+25.6% | $36.8M+27.5% | $35.63M+35.3% | $34.01M+37.8% | ||
| $199.56M+17.4% | $191.41M+20.5% | $180.97M+23.0% | $174.54M+28.2% | $170.04M+37.8% | ||
| -$199.56M-17.4% | -$191.41M-20.5% | -$180.97M-23.0% | -$174.54M-28.2% | -$170.04M-37.8% | ||
| -$176.01M-20.5% | -$167.8M-25.4% | -$157.24M-26.5% | -$150.7M-30.1% | -$146.09M-38.0% | ||
| -$1.67-7.7% | -$1.64-13.1% | -$1.58-5.3% | -$1.550.0% | -$1.550.0% | ||
| -$197.5M-17.6% | -$189.37M-20.8% | -$178.88M-23.2% | -$172.45M-28.4% | -$167.95M-38.1% | ||
| -$199.56M-17.4% | -$191.41M-20.5% | -$180.97M-23.0% | -$174.54M-28.2% | -$170.04M-37.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Edgewise Therapeutics, Inc. profitable?
- Edgewise Therapeutics, Inc. is not currently profitable: it reported a net loss of $176.0M over the trailing twelve months.
- What is Edgewise Therapeutics, Inc.'s earnings per share?
- Edgewise Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.67.
- Where does Edgewise Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.